Re: What's Next?

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

chicagoest

Rank: President [?]

Points: 1974 [?]

Votes: 20 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: What's Next?

in response to

What's Next?

SanFrancisco99

posted on Mar 11, 2016 08:13PM

SanFrancisco99

Below is an earlier post I made summarizing various catalysts that could propel this stock which has been refined and added to by many on this board. IMHO we will be in a wait and hold period for 6 to 12 months. One high priority that must be resolved quite soon is the financing of the Zenith trial and operations which could spawn a regional partnership or bring in a new player. I agree with your post and also hope that Resverlogix will announce an orphan trial and possibly other promising compound(s) in the next 6-12 months. If RVX is what they sez it is and we all believe it to be, then BP will step in, but not until they have proof of concept or FDA approval. The Hepa deal and $46MM cash infusion at a substantial premium to market is a strong indication that RVX-208 is a viable and marketable therapy - I'm not sure if I would still be holding RVX if it weren't for the life saving Hepa deal.

A Critical Mass

in response to Zenith AGM is come and gone... by kelsee

posted on Jan 09, 16 09:09PM Use the IP Check tool [?]

One day in the not too distant future these two epigenetic pioneers will reach the state of critical mass and explode. It may be 6, 12, 18, 24 months away - we must be patient - it's coming and it's going to be big. Several catalysts are out there and any could start the reaction.

RVX-208 BetonMace Trial approved by FDA

RVX partners with BP

RVX acquired by BP

BetonMace trial successfully reaches endpoints

RVX Nasdaq listing

RVX upgraded to Strong Buy

RVX receives major institutional coverage

Resverlogix commences Phase 1 trial for promising new Alzheimers treatment

Resverlogix begins new trial on orphan indication

Zenith acquires Nasdaq listing

Zenith lists on TSX

ZEN-3694 success

Zenith announces new trial for treatment of breast cancer

RVX holds RVX-208 and about 2500 other compounds

ZEL holds ZEN-3694 and 1500 other compounds

To hold this 'diamond in the rough' at this point in time and at this price is an unbelievable opportunity - Hallelujah!